<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540355</url>
  </required_header>
  <id_info>
    <org_study_id>EMS0717</org_study_id>
    <nct_id>NCT03540355</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment</brief_title>
  <official_title>Phase III, National, Multicenter, Randomized, Double-blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 20 Association on the Dyslipidemia Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Cipros 20 association in the
      treatment of dyslipidemia treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of serum triglyceride levels</measure>
    <time_frame>12 weeks vs baseline</time_frame>
    <description>The reduction of triglyceride levels will be measured through the difference of values in the first visit and last visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of serum LDL-c</measure>
    <time_frame>12 weeks vs baseline</time_frame>
    <description>The reduction of serum-LDL-c will be measured through the difference of values in the first and last visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events recorded during the study</measure>
    <time_frame>13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">312</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Cipros 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study is double-masked, the patient will take 2 tablets, as follow:
1 tablet Cipros 20 association; and
1 tablet crestor placebo. Oral, once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crestor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study is double-masked, the patient will take 2 tablets, as follow:
1 tablet Crestor 20 mg; and
1 tablet cipros association placebo. Oral, once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cipros 20 association</intervention_name>
    <description>oral, once a day</description>
    <arm_group_label>Cipros 20</arm_group_label>
    <other_name>EMS Association</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 20 mg</intervention_name>
    <description>Oral, once a day</description>
    <arm_group_label>Crestor</arm_group_label>
    <other_name>Rosuvastatin 20 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes, aged 18 years or more;

          -  Participants with the diagnosed of dyslipidemia and with high or very high
             cardiovascular risk, according to the Brazillian Guidelines on Dyslipidemia and
             Prevention of Atherosclerosis;

          -  Signed consent.

        Exclusion Criteria:

          -  Using medications that may interfere with the metabolism or serum levels of
             triglycerides;

          -  Any clinical and laboratory findings that, in the judgment of the investigator, may
             interfere with the safety of research participants;

          -  Presence of concomitant cardiovascular disease, renal failure and hepatic failure;

          -  Decompensated diabetes;

          -  Current smoking;

          -  History hypersensitivity to the active ingredients used in the study;

          -  Pregnancy or risk of pregnancy and lactating patients;

          -  History of alcohol abuse or illicit drug use;

          -  Participation in clinical trial in the year prior to this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Monalisa F.B Oliveira, M.D.</last_name>
    <phone>+55193887-9851</phone>
    <email>pesquisa.clinica@ems.com.br</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>May 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

